AI
RVNC

Accredited Investors’s Revance Therapeutics, Inc. RVNC Stock Holding History

Accredited Investors’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12,845
Closed -$66.7K – 247
2024
Q3 		$66.7K Buy
+12,845
New +$63.8K ﹤0.01% 232
2024
Q2 		– Sell
-12,845
Closed -$63.2K – 233
2024
Q1 		$63.2K Hold
12,845
– – ﹤0.01% 209
2023
Q4 		$113K Hold
12,845
– – 0.01% 192
2023
Q3 		$147K Hold
12,845
– – 0.01% 188
2023
Q2 		$325K Sell
12,845
-7,646
-37% -$238K 0.02% 139
2023
Q1 		$660K Hold
20,491
– – 0.05% 93
2022
Q4 		$378K Hold
20,491
– – 0.03% 122
2022
Q3 		$553K Hold
20,491
– – 0.06% 93
2022
Q2 		$283K Hold
20,491
– – 0.03% 142
2022
Q1 		$400K Hold
20,491
– – 0.04% 129
2021
Q4 		$334K Hold
20,491
– – 0.03% 138
2021
Q3 		$571K Hold
20,491
– – 0.06% 95
2021
Q2 		$607K Hold
20,491
– – 0.06% 95
2021
Q1 		$573K Hold
20,491
– – 0.08% 90
2020
Q4 		$581K Buy
+20,491
New +$531K 0.1% 87

Other funds holding RVNC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Accredited Investors's RVNC Position: Q4 2024 in Review

Accredited Investors sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2024, closing a stake of 12,845 shares — an estimated $66.7K sold.

Accredited Investors first reported a position in RVNC in Q4 2020 and held it in 15 quarters. The position peaked at $660K in Q1 2023. 173 funds tracked by Wall St. Rank hold RVNC as of Q4 2024.

  • Accredited Investors reported no remaining Revance Therapeutics, Inc. position as of Q4 2024 after selling out during the quarter.
  • Accredited Investors sold 12,845 Revance Therapeutics, Inc. shares in Q4 2024, an estimated $66.7K.
  • Accredited Investors first reported a position in Revance Therapeutics, Inc. in Q4 2020 and held it in 15 quarters.
  • Accredited Investors's Revance Therapeutics, Inc. position peaked at $660K in Q1 2023.
  • 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2024.

Based on Accredited Investors's 13F filing for Q4 2024, filed 13 Feb 2025.